Psilocybin therapy is not legal in California. Psilocybin is a Schedule I controlled substance under both California and federal law, no state-licensed therapy program exists, and every bill that would have created one has either failed in the legislature or been vetoed by the Governor. The bills moving through Sacramento in 2025 and 2026 authorize research, not treatment.
How California and Federal Law Classify Psilocybin
California lists psilocybin as a Schedule I hallucinogenic substance under Health and Safety Code Section 11054(d)(18).1California Legislative Information. California Code, Health and Safety Code HSC 11054 Schedule I is the state’s most restrictive tier, reserved for substances treated as having high abuse potential and no accepted medical use.
Federal law matches that classification. Under 21 U.S.C. § 812, psilocybin is a Schedule I controlled substance with, in the statute’s own words, “no currently accepted medical use in treatment in the United States” and no “accepted safety for use…under medical supervision.”2Office of the Law Revision Counsel. 21 USC 812 Schedules of Controlled Substances
The dual classification matters. Even if California eventually authorizes psilocybin therapy at the state level, federal prohibition would remain, producing the same state-versus-federal conflict that defines the marijuana industry.
Criminal Exposure for Possession, Distribution, and Facilitated Use
Simple possession of psilocybin falls under Health and Safety Code Section 11377. After Proposition 47 passed in 2014, simple possession of most controlled substances was reclassified as a misdemeanor punishable by up to a year in county jail.3Judicial Council of California. Proposition 47 Frequently Asked Questions People with prior convictions for certain serious violent felonies or registrable sex offenses can still be charged with a felony for simple possession.
Proposition 36, approved by voters in November 2024, created a “treatment-mandated felony” track for repeat drug offenders. That provision is aimed at substances like fentanyl, heroin, cocaine, and methamphetamine rather than psilocybin.4Legislative Analyst’s Office. Proposition 36
Distribution is a different category of risk. Possessing psilocybin with intent to sell, or selling, transporting, or furnishing it, are felony offenses under Health and Safety Code Sections 11378 and 11379, with potential state prison sentences. Anyone offering psilocybin “therapy” without legal authorization is distributing a Schedule I substance in the eyes of the law, no matter how the service is marketed.
Federal exposure is independent and heavier. For any amount of a Schedule I substance, a first distribution offense carries up to 20 years in federal prison and fines up to $1 million for an individual. If death or serious injury results, the minimum rises to 20 years with a possible life sentence; a second offense raises the ceiling to 30 years, with mandatory life imprisonment if someone dies.5U.S. Drug Enforcement Administration. Federal Trafficking Penalties A state license, if one existed, would not be a defense in federal court.
Local Deprioritization Is Not Legalization
Several California cities have passed resolutions directing police to treat enforcement of psilocybin laws as the lowest priority. Oakland did so in June 2019, with the city council voting unanimously that city funds would not be used to help enforce criminal penalties for the use and possession of entheogenic plants, a category that includes psilocybin mushrooms. The resolution did not permit commercial sale or manufacturing. Santa Cruz, Arcata, Berkeley, and San Francisco have adopted similar measures.
None of these resolutions change state or federal law. Police can still arrest, district attorneys can still file charges, and federal agents are unaffected. Deprioritization offers practical breathing room in those cities; it provides no legal defense if a case is actually brought.
Why There Is No Legal Therapy Framework Yet
California has tried, and failed, to authorize psilocybin use several times.
Senator Scott Wiener’s Senate Bill 519, introduced in the 2021–2022 session, would have made it lawful for people 21 and older to possess, obtain, give away, or transport specified quantities of psilocybin, DMT, mescaline, LSD, MDMA, and ibogaine for personal use or “facilitated or supported use,” and would have directed the State Department of Public Health to convene a working group on regulations.6California Legislative Information. California Senate Bill 519 It did not pass.
A narrower follow-up, Senate Bill 58, covered psilocybin, psilocyn, DMT, and mescaline. It passed both chambers but was vetoed by Governor Newsom on October 7, 2023. In his veto message, the Governor wrote that “this bill would decriminalize possession prior to these guidelines going into place, and I cannot sign it,” and he called on the legislature to first establish regulated treatment guidelines, including “dosing information, therapeutic guidelines, rules to prevent against exploitation during guided treatments, and medical clearance of no underlying psychoses.”7Governor of California. Senate Bill 58 Veto Message
Senator Wiener responded in 2024 with SB 1012, titled the Regulated Psychedelic Facilitators Act and the Regulated Psychedelic-Assisted Therapy Act. It would have created a licensing board, required regulations by January 1, 2026, and begun accepting facilitator license applications by April 1, 2026, covering psilocybin, psilocyn, DMT, mescaline, and MDMA.8California Legislative Information. SB 1012 The Regulated Psychedelic Facilitators Act Violations by facilitators would generally have been misdemeanors carrying up to six months in county jail, fines up to $2,500, or both, with sexual exploitation during treatment punishable by up to three years in state prison and fines up to $10,000 for aggravated cases. SB 1012 did not advance out of the legislature.
What Is Moving in 2025 and 2026
With broad decriminalization and a full therapy framework both stalled, lawmakers have shifted to incremental research bills, several of them focused on veterans and first responders:
- AB 1103, signed into law in October 2025, streamlines state review of psychedelic research studies by allowing a smaller cohort of the Research Advisory Panel to approve qualifying applications instead of requiring a full panel vote.
- SB 751, introduced by Senator Josh Becker with bipartisan co-sponsorship, would create a Veterans and Former First Responders Research Pilot Program, asking the University of California to set up pilot programs in up to five counties. Psilocybin would be administered under practitioners experienced in psychedelic therapy, with participants required to be 21 or older and to complete specified assessments.9Plural Policy. SB 751 California 2025-2026
- AB 2489 would allow California’s Research Advisory Panel to submit FDA applications for clinical trials using Schedule I and II controlled substances, including psilocybin, specifically for veterans.
None of these bills open psilocybin therapy to the general public. They build out a research track that could support broader access later.
Legal Ways to Access Psilocybin Therapy Right Now
For someone in California who wants legal access to psilocybin therapy, the realistic options are narrow:
- Enroll in an FDA-approved clinical trial. COMPASS Pathways received a Breakthrough Therapy Designation from the FDA in 2018 for psilocybin therapy targeting treatment-resistant depression, and in February 2026 the FDA granted a separate Breakthrough Therapy Designation to Reunion Neuroscience for luvesilocin, a psilocybin-related compound, for postpartum depression, with a Phase 3 trial planned for 2026. Breakthrough status is not approval; it is expedited development and review.
- Travel to Oregon. Oregon is the only state with an operational psilocybin therapy framework, created by Measure 109 in 2020. Psilocybin is administered only at licensed service centers under licensed facilitators, with no retail sales and no take-home supply.
- Wait for California’s legislative process to produce a signed law. SB 1012 borrowed heavily from Oregon’s supervised model, and if California eventually passes a therapy framework, it is likely to resemble that structure rather than a retail or home-use system.
Underground psilocybin “therapy” sits outside all of these paths. Providers face felony state distribution charges, federal trafficking exposure, and loss of any professional healthcare license; patients face misdemeanor possession exposure and none of the oversight — purity testing, standardized dosing, screening for contraindicated conditions such as psychotic disorders, or legal recourse if something goes wrong — that a regulated program would supply. The safeguards Governor Newsom and the legislature have been arguing over do not exist yet, and that absence is the point.